Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors — Stella

Home/Neuroendocrine Tumors/

View on ClinicalTrials.gov

Recruiting

Back to Neuroendocrine Tumors trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(2 sites)

Brazil

AC Camargo Cancer Center, São Paulo, São Paulo

AC Camargo Cancer Center, São Paulo

Key details

Phase

Safety & dosing

Sponsor

AC Camargo Cancer Center

Enrollment target

~100 participants

Started

April 2024

Primary completion

May 2026

Age range

16 Years and older

Last updated June 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.